We are pleased to report a milestone achievement by Dr. Aviad Zick, a senior medical oncologist at Hadassah. Known for his profound interest in the translation of DNA characterization to oncological care, Dr. Zick has now led the introduction of the New England Alpelisib for the treatment of Intractable Non-Islet Cell Tumor Hypoglycemia.
Dr. Zick’s work extends to the crucial domain of identifying germline mutations in the patient population. His consistent dedication and the depth of his research in this field have significantly contributed to the understanding and management of complex oncological conditions.
As a key member of the Hadassah Clinical Research Institute and the Sharett Institute of Oncology, Dr. Zick’s commitment to medical research has borne fruit with the development of the New England Alpelisib. This breakthrough is a result of his rigorous research, his innovative thinking, and a testament to his tireless efforts.
Intractable Non-Islet Cell Tumor Hypoglycemia presents complex challenges that necessitate innovative and effective treatment approaches. The New England Alpelisib, under Dr. Zick’s guidance, offers promising new possibilities for patient management and care.
We extend our appreciation to Dr. Zick for his noteworthy contributions to oncology and wish him continued success in his future research endeavors.
Link to the Article >>https://www.nejm.org/doi/pdf/10.1056/NEJMc2302935
#HCRI #SharettInstituteofOncology #Hadassah #Alpelisib #IntractableNonIsletCellTumorHypoglycemia #oncology #medical #research
